SII’s Covovax gets emergency use approval from WHO: why it is being called a milestone The Times of India

Recently, Serum Institute of India (SII) CEO Adar Poonawalla announced plans to launch the Kovovax jab for children in the next six months.

“We have not seen very severe disease in children. Fortunately, there is no panic for children. However, we will launch a vaccine for them in six months, hopefully by the age of three,” he said.

He added, “Our Kovovax vaccine, which is under trial and which has shown excellent data all the way to age three, will be launched in six months.” It was only a matter of time before Covovax was approved for emergency use by the WHO.

Apart from his statement of launching the vaccine, he also highlighted the importance of immunizing children. “Yes, I think you should get your kids vaccinated. There is no harm in that, these vaccines have been proven to be safe and effective. Just wait for the announcement from the government, and then you can move on,” he said.

As of now, people aged 18 years and above in the country are eligible for vaccination. Currently, only one of the coronavirus vaccines given Emergency Use Authorization (EUA) by the Drug Controller General of India (DCGI), ZyCoV-D from Ahmedabad-based Zydus Cadila, is available for all people aged 12 years and above. Approval has been given.

,